Because regulatory approval of cognitive enhancement drugs is likely, physicians may want to consider whether they would condone the practice for restoration of function only or for enhancement purposes as well.
Institutional review boards (IRBs) have the responsibility to ensure the protection of human-research subjects and are legally liable if they fail to do so.
Though body size can be altered with environmental or behavioral changes, anatomic shape, which appears to be genetically determined, cannot be changed except by surgery, trauma, or illness.
The Supreme Court’s ruling in Riegel v. Medtronic, Inc., may prevent consumers injured by medical devices that have FDA premarket approval from receiving compensation.
According to documented studies, patients who have good relationships with their physicians are less likely to file complaints in the event of an adverse medical outcome.
There is a market for direct-to-consumer genetic testing and a need for better consumer information and more regulation of tests and testing laboratories.